"MAP Kinase Kinase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An abundant 43-kDa mitogen-activated protein kinase kinase subtype with specificity for MITOGEN-ACTIVATED PROTEIN KINASE 1 and MITOGEN-ACTIVATED PROTEIN KINASE 3.
| Descriptor ID |
D048369
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565.100 D08.811.913.696.620.682.725.200.100 D12.644.360.440.100 D12.776.476.440.100
|
| Concept/Terms |
MAP Kinase Kinase 1- MAP Kinase Kinase 1
- MKK1 Protein Kinase
- MAP2K1 Protein
- Mitogen-Activated Protein Kinase Kinase 1
- Mitogen Activated Protein Kinase Kinase 1
- MKK-1 Protein Kinase
- MKK 1 Protein Kinase
- MEK-1 Protein Kinase
- MEK 1 Protein Kinase
- MAPK Kinase 1
- MEK1 Protein Kinase
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase 1".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase 1".
This graph shows the total number of publications written about "MAP Kinase Kinase 1" by people in this website by year, and whether "MAP Kinase Kinase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 3 | 0 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 2 | 4 |
| 2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "MAP Kinase Kinase 1" by people in Profiles.
-
mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK. Cancer Res. 2021 06 15; 81(12):3174-3186.
-
Constitutive activation of mitogen-activated protein kinase kinase (MEK1) in ileal enterocytes leads to dysplasia and a predisposition to cancer. Am J Physiol Gastrointest Liver Physiol. 2021 03 01; 320(3):G366-G379.
-
BRAFV 600E or mutant MAP2K1 human CD34+ cells establish Langerhans cell-like histiocytosis in immune-deficient mice. Blood Adv. 2020 10 13; 4(19):4912-4917.
-
MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC. JCI Insight. 2020 08 06; 5(15).
-
An activator of G protein-coupled receptor and MEK1/2-ERK1/2 signaling inhibits HIV-1 replication by altering viral RNA processing. PLoS Pathog. 2020 02; 16(2):e1008307.
-
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020 04; 85(4):673-683.
-
Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res. 2019 10; 29(5):522-526.
-
Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jun; 175(2):339-351.
-
Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2018 09; 65(9):e27237.
-
Prolonged Mek1/2 suppression impairs the developmental potential of embryonic stem cells. Nature. 2017 08 10; 548(7666):219-223.